Umoja and AbbVie chase Interius with in vivo Car-T
The companies hopes to be as efficacious as ex vivo therapy, with convenience and safety advantages.
Scancell faces its big decision
Data in the coming months will inform which immunotherapy the UK company takes into pivotal development.
IO Biotech looks for an interim injection
The group plays down upcoming interim analysis, but still hopes for accelerated approval.
Merck seeks the next Keytruda
The group’s Kelun-partnered TROP2 ADC looks like a bargain, but Merck’s pipeline has big shoes to fill.
We haven't lost focus, BioNTech insists
The company defends its cancer strategy, and says it's not a me-too developer.
ASCO 2024 – J&J shifts to a new radiopharma dosing strategy
The group is keeping faith with the novel target KLK2.
ASCO 2024 preview – jury still out on AbbVie's cancer push
SEZ6 looks promising but early, while questions remain around toxicity with AbbVie's cMet ADCs.
FibroGen throws down the prostate cancer gauntlet
Amid doubts about early data with FG-3246, the group is scathing about its rivals.
Mythic goes back to basics
More efficient internalisation and release – not bystander activity – are the focus for this private ADC player.
Volastra vies for the next big synthetic lethality target
The group reckons big pharma is eyeing KIF18A inhibition, but for now there are just a handful of players.
